metformin has been researched along with Soft Tissue Neoplasms in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hutchinson, ID | 1 |
| Ata, A | 1 |
| DiCaprio, MR | 1 |
| Mayerson, JL | 1 |
2 other studies available for metformin and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Is Metformin Use Associated with Prolonged Overall Survival in Patients with Soft Tissue Sarcoma? A SEER-Medicare Study.
Topics: Aged; Humans; Medicare; Metformin; Prospective Studies; Retrospective Studies; Sarcoma; SEER Program | 2022 |
CORR Insights®: Is Metformin Use Associated with Prolonged Overall Survival In Patients with Soft Tissue Sarcoma? A SEER-Medicare Study.
Topics: Aged; Humans; Medicare; Metformin; Sarcoma; Soft Tissue Neoplasms; United States | 2022 |